Journal decision profile

Clinical & Experimental Metastasis

Medicine · Biochemistry, Genetics and Molecular Biology

Clinical & Experimental Metastasis' 2026 Journal Metrics Score is 4.0, ranking Q1 in Oncology and 1 other subfield. Two-year citation average from OpenAlex data, updated August 2026.

Springer Science+Business MediaNetherlandspISSN 0262-0898eISSN 1573-7276
Checking system sharing availability.Visit homepage

Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.

Journal Metrics Score
i
Journal Metrics ScoreThe raw score is citations received in the latest complete year by works from the two previous years, divided by the number of those works. It is calculated from OpenAlex open data (CC0) and is not a percentage grade.
2026
4.0

Journal Metrics Score 2026 · 2021–2024 window citedness 3.43.

Review & acceptance time
i
Review & acceptance timeCalendar days between the received and accepted dates reported in recent PubMed records. This interval includes editorial handling and author revisions, so it is not time to first decision or pure peer-review time.
PUBMED
100 daysmedian

Middle 50%: 73–148 days

100 of 100 PubMed-indexed articles · 100% coverage · 2024–2025

Clinical & Experimental Metastasis accepts papers a median of 100 days after submission, including peer review and revisions. That is faster than 58% of comparable journals with PubMed timing data.

Indicative APC
i
Indicative APCThis journal-level estimate comes from the OpenAlex source record. It is not a verified quote and may exclude taxes, waivers, society discounts, or article-type charges. Check the journal's official website before deciding.
OPENALEX · VERIFY
$5,090

Journal-level estimate only. Verify current charges, taxes, waivers, discounts, and article-type fees with the journal.

Free preview · no sign-in

Does your manuscript fit Clinical & Experimental Metastasis?

Paste your title to see which of this journal's published topics it overlaps with. Your title stays in your browser for this preview and is not sent anywhere.

Want ranked journals with fit reasons, risks and a submission strategy instead? See a sample AI report.

At a glance

Journal decision profile

Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.

Relative profile

Metrics ScoreThe raw 2026 Journal Metrics Score is the recent two-year citation average shown above. The radar converts it to a 0–100 cohort percentile: farther out means a higher score than more comparable journals. It is not a percentage grade.iSource outputThe raw rank compares lifetime output inside the journal’s leading-topic source set. The radar then compares that rank position across Decision Profile journals in the same primary OpenAlex field; when that field has too few profiles, it uses the broader profile set. Farther out means relatively more output, not better research quality.iTop 10% shareThe share of recent papers in the global top 10% for citations after comparing papers of the same type, publication year, and subfield. The radar converts that share to a 0–100 cohort percentile; it does not predict how a new paper will perform.iMedian FWCICitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected citation level for comparable papers; the radar shows its 0–100 cohort percentile.iSubmission-to-acceptanceCalendar days from the received date to the accepted date in recent PubMed records. This includes editorial handling and author revisions, so it is not the time to first decision and not pure peer-review time. The radar uses a 0–100 cohort percentile with shorter observed timing plotted farther out; it does not measure review quality.iOutput volumeAverage works published per year in the recent analysis window, converted to a 0–100 cohort percentile. Farther out means the journal publishes more papers; it does not mean those papers are better.i
Cost is intentionally excluded. Missing APC data is never converted to a zero-dollar fee or a fabricated cost score.

Raw values behind the shape

Always visible
Metrics Score
i
Metrics ScoreThe 2026 raw Journal Metrics Score shown above. The bar is its 0–100 percentile within the radar's comparable journal cohort; it is not a percentage score.
4.02026 · OPENALEX
Source output rank
i
Source output rankThis lifetime journal-wide output rank compares works published by the OpenAlex source with sources associated with the journal’s leading topic. More output does not mean higher quality.
#164 / 1,113LIFETIME OUTPUT
Highly cited papers
i
Highly cited papersShare of recent works in the global top 10% for citations after comparing papers of the same type, publication year, and subfield.
15.6%FIELD-NORMALIZED TOP 10%
Field-normalized impact
i
Field-normalized impactCitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected level for comparable work.
0.92MEDIAN FWCI
Submission-to-acceptance
i
Submission-to-acceptanceReceived-to-accepted calendar days from qualified PubMed records. It includes editorial handling and author revisions; it is not time to first decision or pure peer-review time.
100 daysIQR 73–148 DAYS
Recent output
i
Recent outputAverage works published per year across the complete analysis window. This is a volume measure, not a quality score.
64 / yr2021–2024 AVG
Field-normalized top 10% share15.6%

40 of 257 works · same type, year & subfield

Field-normalized top 1% share0%

0 works · same type, year & subfield

Median FWCI0.92×

Below field-year expectation

Source output rank#164

of 1,113 topic-associated OpenAlex sources by lifetime output

What does Median FWCI mean?

FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 0.92, so its typical recent paper runs about 8% below its field benchmark.

What does Top 10% Share mean?

15.6% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.

Publishing pattern

Publication volume and article mix

Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.

Works published by year

OpenAlex source records · 2016–2025

562016
452017
732018
692019
502020
722021
572022
532023
752024
592025

Recent work-type mix

257 OpenAlex works · 2021–2024

Article91.4%
Review3.9%
Erratum3.5%
Editorial0.8%
Paratext0.4%
OpenAlex article is broader than “original research.” PubMed Publication Types can add case-report and clinical-study detail.
Fit signals

Topics and medical subject coverage

OpenAlex topics show research communities; MeSH keeps the medical taxonomy recognizable.

Major MeSH signals

PubMed-indexed works

Select a MeSH signal to see how much Clinical & Experimental Metastasis publishes on it, from PubMed counts for the last five complete years.

Leading OpenAlex topics

2021–2024 works
Cancer Cells and Metastasis31
Brain Metastases and Treatment20
Cutaneous Melanoma Detection and Management11
Breast Cancer Treatment Studies10
Cancer Immunotherapy and Biomarkers10
Lymphatic System and Diseases9
Colorectal Cancer Treatments and Studies6
Management of metastatic bone disease6
Prostate Cancer Diagnosis and Treatment6
Intraperitoneal and Appendiceal Malignancies5
Methodology: OpenAlex snapshot 2026-10-25. FWCI, percentile badges, topics, and type mix use 257 works published 2021–2024. Radar normalization is versioned in the cached profile, and no cost score is assigned without reliable APC data.

Subject Category Quartiles

Quartiles computed within each OpenAlex subfield
CategoryQuartile
OncologyQ1
Immunology and AllergyQ1
Cancer ResearchQ2

Is Clinical & Experimental Metastasis a good journal?

Yes. A Q1 journal by citation data

Yes. By citation data, Clinical & Experimental Metastasis is a strong journal: it is Q1 in Oncology and 1 other subfield and ranks #810 of 6,272 Medicine journals by Journal Metrics Score (top 13%). Clinical & Experimental Metastasis' 2026 Journal Metrics Score is 4.0. Recent papers took a median of 100 days from submission to acceptance, according to PubMed dates. OpenAlex lists an indicative article processing charge of $5,090 USD. OpenAlex classifies its papers in subfields including Oncology, Immunology and Allergy, and Cancer Research, so check that your topic fits its scope.

Best quartile
Q1
Oncology
Rank in Medicine
#810 of 6,272
Top 13%
2026 Journal Metrics Score
4.0
Acceptance rate
Not published
By the journal or publisher
Submission to acceptance
100 days
Median, PubMed records
Indicative APC
$5,090
OpenAlex, verify with the journal
Papers published in 2025
59
OpenAlex works

Check before you submit

  • Confirm the current article processing charge, waivers, and any institutional agreement on the journal website; the OpenAlex figure is indicative.
  • Confirm the journal is indexed where your institution or funder requires (for example Scopus or PubMed) before you submit.

Verdict from citation data only: quartile and field rank by Journal Metrics Score (OpenAlex), publisher-reported acceptance rates, and PubMed submission and acceptance dates. See how we rank journals and how to verify indexing.

Q1
Subfield Quartile
B3
CAS Block

Ranking and source check

#810
of 6,272 Medicine field journals
#807
among Q1 Medicine journals

Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.

Journal Details

OpenAlex Works
2,789
H-Index
127
Fully Open Access
No
Recent OA Works
508
Subject Areas
OncologyImmunology and AllergyCancer Research

Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.

How to submit to Clinical & Experimental Metastasis

  1. 1

    Check the scope

    OpenAlex classifies Clinical & Experimental Metastasis' papers in subfields including Oncology, Immunology and Allergy, and Cancer Research. Read the aims and scope page and a few recent papers close to your topic before you prepare the manuscript.

  2. 2

    Follow the author guidelines

    Article types, word and figure limits, reference style, and the required statements (data availability, ethics, conflicts of interest, author contributions) are set by the journal. Prepare the cover letter and files to match them.

    Clinical & Experimental Metastasis homepage ↗
  3. 3

    Submit online

    Use the submit link in Clinical & Experimental Metastasis' author guidelines; Springer Science+Business Media runs the submission site. Every author usually needs an ORCID iD, and the corresponding author needs an account on the submission site.

  4. 4

    Plan for costs

    OpenAlex lists an indicative article processing charge of $5,090 USD. Check the current fee, waivers, and any institutional agreement on the journal website.

  5. 5

    Know what to expect

    Recent accepted papers took a median of 100 days from submission to acceptance, including revisions (PubMed dates). Clinical & Experimental Metastasis does not publish an acceptance rate.

New on PubMed

What's new in your field?

Type a topic to see the newest PubMed papers from the past week and the big picture of what they found, summarized by Claude on the Pro plan. Get a free weekly email to keep up.

See a demo:GLP-1CRISPRLong COVID

Reviewer Two · coming soon

Know what reviewers will say before you submit to Clinical & Experimental Metastasis

An AI pre-submission report on your manuscript: the objections a tough reviewer is likely to raise, desk-rejection risks, and better-fit journals from our data. $29 per report.

See what the report covers

Common questions about Clinical & Experimental Metastasis

Is Clinical & Experimental Metastasis a good journal?

Yes. By citation data, Clinical & Experimental Metastasis is a strong journal: it is Q1 in Oncology and 1 other subfield and ranks #810 of 6,272 Medicine journals by Journal Metrics Score (top 13%). Clinical & Experimental Metastasis' 2026 Journal Metrics Score is 4.0. Recent papers took a median of 100 days from submission to acceptance, according to PubMed dates. OpenAlex lists an indicative article processing charge of $5,090 USD. OpenAlex classifies its papers in subfields including Oncology, Immunology and Allergy, and Cancer Research, so check that your topic fits its scope.

What is Clinical & Experimental Metastasis' Journal Metrics Score in 2026?

Clinical & Experimental Metastasis' 2026 Journal Metrics Score is 4.0, from the August 2026 data release. The score is a two-year citation average computed from OpenAlex (CC0) data: citations received in the most recent complete year to works published in the two prior years, divided by the number of those works.

What is the acceptance rate of Clinical & Experimental Metastasis?

We have not found an official acceptance rate published by Clinical & Experimental Metastasis or its publisher, and Journal Metrics does not estimate one because submission counts are not public. What recent PubMed records do show is speed: accepted papers took a median of 100 days from submission to acceptance. To judge selectivity, compare Clinical & Experimental Metastasis' quartile and score with similar journals, or ask the editorial office.

What quartile is Clinical & Experimental Metastasis in?

Clinical & Experimental Metastasis' best quartile is Q1. By OpenAlex subfield: Q1 in Oncology; Q1 in Immunology and Allergy; Q2 in Cancer Research. Quartiles rank journals by Journal Metrics Score within each subfield.

Is the Journal Metrics Score the same as other journal citation metrics?

No. Journal Metrics computes the score independently from OpenAlex open data. Other providers use different citation databases, document types, and counting rules, so their published figures for Clinical & Experimental Metastasis will not match this score exactly. Compare journals using one source at a time.

How long does Clinical & Experimental Metastasis take to accept a paper?

Clinical & Experimental Metastasis accepts papers a median of 100 days after submission across 100 recent PubMed records with both dates; the middle half took 73–148 days. This includes peer review, editorial handling, and revisions.

How long is the peer review time at Clinical & Experimental Metastasis?

PubMed records when a manuscript was received and accepted, not the individual review stages, so peer review time on its own is not available. The full time from submission to acceptance at Clinical & Experimental Metastasis, which includes peer review and revisions, has a median of 100 days. For the time to a first decision, check the journal's own website.

Is Clinical & Experimental Metastasis faster than similar journals?

Clinical & Experimental Metastasis' median of 100 days from submission to acceptance is faster than 58% of comparable journals with PubMed timing data.

How much does it cost to publish in Clinical & Experimental Metastasis?

OpenAlex lists an indicative article processing charge of $5,090 USD for Clinical & Experimental Metastasis. This journal-level estimate may exclude taxes, waivers, discounts, or article-type fees, so confirm the current charge on the journal's website.

Which journals are alternatives to Clinical & Experimental Metastasis?

Comparable journals include Nature Cancer, Cancer and Metastasis Reviews, Cancer Treatment Reviews, and British Journal of Cancer. Compare their scores, acceptance times, and costs in the recommended alternatives on this page before choosing where to submit.

How do I submit a paper to Clinical & Experimental Metastasis?

Submit online through the link in Clinical & Experimental Metastasis' author guidelines on the journal homepage. Before submitting, check the scope, follow the author guidelines for article type, length, and required statements, and prepare a cover letter. Accepted papers took a median of 100 days from submission to acceptance in recent PubMed records.

Cite an article from this journal
Back to Search